SCHEMBL756988

SCHEMBL756988

COC(=O)c1ccc2c(c1)OC(C)(C)C(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 11/20 0.56
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ALOX5 P09917 1/20 0.50
POLB P06746 2/20 0.46
HPGD P15428 1/20 0.46
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.43
CREBBP Q92793 1/20 0.43
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
XDH P47989 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2238148 0.89 ALDH1A1 (0.69) BRD4ALDH1A1KDM4ESMN1; SMN2ALOX5
SCHEMBL9462366 0.84 KDM4E (0.55) BRD4ALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL27375663 0.82 ALOX5 (0.47) BRD4ALDH1A1KDM4ESMN1; SMN2ALOX5
SCHEMBL9588979 0.80 ALDH1A1 (0.54) BRD4ALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL24427943 0.79 ALDH1A1 (0.53) BRD4ALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL2240754 0.79 BRD4 (0.52) BRD4ALDH1A1KDM4ESMN1; SMN2ALOX5
SCHEMBL23589336 0.77 ALDH1A1 (0.48) BRD4ALDH1A1KDM4ESMN1; SMN2PDE3B
SCHEMBL17026958 0.76 BRD4 (0.48) BRD4ALDH1A1KDM4ESMN1; SMN2PDE3B
SCHEMBL24427946 0.76 BRD4 (0.49) BRD4ALDH1A1KDM4ESMN1; SMN2POLB
SCHEMBL23011988 0.75 BRD4 (0.51) BRD4ALDH1A1KDM4ESMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8188073-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
EP-1984345-B9 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORP (JP) 2012-03-21 EP disclosed
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS IIJIMA TORU 2011-10-13 US disclosed
EP-1984345-B1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORP (JP) 2011-08-31 EP disclosed
US-7998956-B2 Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-16 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
EP-2168952-A1 MORPHOLINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-01-22 US disclosed
EP-1984345-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-10-29 EP disclosed
WO-2007089034-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed
CN-1060769-C 1,4-benzoxazine derivatives, pharmaceutical composition containing the same and use thereof KENEBO LTD (JP) 2001-01-17 CN disclosed
EP-0719766-B1 1,4-Benzoxazine derivative, pharmaceutical composition containing the same and use thereof KANEBO LTD (JP) 2000-04-12 EP disclosed
US-5597820-A CARDIOVASCULAR DISORDERS KANEBO, LTD. (JP) 1997-01-28 US disclosed
CN-1130183-A 1,4-benzoxazine derivatives, pharmaceutical composition containing the same and use thereof KANEBO LTD (JP) 1996-09-04 CN disclosed
EP-0719766-A1 1,4-Benzoxazine derivative, pharmaceutical composition containing the same and use thereof KANEBO LTD. (JP) 1996-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 BRD4 230/4885ALDH1A1 2202/4885KDM4E 689/4885
US-20090023716-A1 Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents NR3C2, MC2R, NR3C1 BRD4 203/4885ALDH1A1 2133/4885KDM4E 2881/4885
US-20110251185-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS NR3C2, MC2R, NR3C1 BRD4 203/4885ALDH1A1 2133/4885KDM4E 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.